title: What Pfizer (PFE)'s Phase 3 Oncology Advances Mean for Shareholders
source: Yahoo
date: 2025-10-18
url: https://finnhub.io/api/news?id=489954659f30c3e4a4c82cadffc32632b5d6caa05dd20e3749b3327eebc5a5d2
Astellas Pharma and Pfizer recently announced positive Phase 3 results for PADCEV plus KEYTRUDA in muscle-invasive bladder cancer, while Pfizer reported encouraging findings for TUKYSA in the first-line treatment of HER2-positive metastatic breast cancer. These late-stage clinical successes highlight Pfizer's strengthened oncology pipeline and its potential to address significant treatment gaps, particularly for patients ineligible for standard therapies. We'll now explore how the promising...
